Alizé Pharma - Articles and news items

Jazz Pharmaceuticals acquires 100% of the shares of Alizé Pharma II

Industry news / 11 May 2016 / Victoria White, Digital Content Producer

A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II in a deal valued at up to €18 million…

AZP-531 and its potential in Prader-Willi Syndrome

Blog, Z Homepage promo / 9 May 2016 / Victoria White, Digital Content Producer

In this exclusive interview, Thierry Abribat, president of Alizé Pharma, discusses AZP-531 and its potential as a treatment for Prader-Willi Syndrome…

Promising top-line results for AZP-531 in Prader-Willi Syndrome

Industry news / 26 April 2016 / Victoria White, Digital Content Producer

Alizé Pharma has announced top-line results of a Phase II clinical trial of AZP-531 in patients with Prader-Willi Syndrome (PWS)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+